Updated 9/23/25. The results chart includes audits where the findings have been finalized. Remaining audits are still under review. Information on Corrective Action Plans and Sanctions will be updated once approved by HRSA. HRSA recommends covered entities do not contact audited manufacturers regarding sanctions until a corrective action plan has been approved by HRSA and posted on this website.
Results posted for 5 audits.
| Manufacturer Sort descending | Labeler Codes Reviewed | State | OPA Findings | Sanction | Corrective Action Status |
|---|---|---|---|---|---|
| Aralez Pharmaceuticals, Inc. | 70347 | NJ |
Incorrect 340B OPAIS record – Incorrect entry in 340B OPAIS for address. |
None |
CAP implemented Audit closure date: May 8, 2025 |
Aurobindo Pharma LTDContact InformationSenior Director, Commercial Finance |
65862 13107 48818 55150 59651 68152 72893 |
NJ |
Incorrect 340B OPAIS record – Incorrect entries in 340B OPAIS for address and manufacturer name. Aurobindo charged more than the 340B ceiling price. |
Repayment to covered entities |
CAP approved |
Cycle Pharmaceuticals, Ltd.Contact InformationAssociate Manager |
70709 | MA |
Cycle did not determine the difference between the new drug estimate and the actual 340B ceiling price and offer a refund. |
Repayment to covered entities |
CAP approved |
| Mayne Pharma Inc. |
68308 50261 51862 |
NC |
No adverse findings |
None |
N/A Audit closure date: July 2, 2025 |
Rhodes Pharmaceuticals LPContact InformationDirector, Pricing Operations |
42858 59011 72912 |
NC |
Rhodes charged more than the 340B ceiling price. |
Repayment to covered entities |
CAP implemented Audit closure date: September 11, 2025 |